Clinical effects of autologous dendritic cells combined with anti-virus therapy on chronic hepatitis B virus infection

Li-Xin Tong,Shu-Xian Liu,Li-Hong Guo,Wei Duan,Bai-Li Chen,Hai-Fang Wang,Li-Ping Liu,Wei Shen,Shu-Yun Wang
DOI: https://doi.org/10.3969/j.issn.1009-3079.2007.11.010
2007-01-01
World Chinese Journal of Digestology
Abstract:AIM:To evaluate the clinical effects of autologous HBsAg-loaded dendritic cells (DCs) combined with anti-viral treatment on patients with chronic hepatitis B virus (HBV) infection. METHODS:A total of 41 chronic HBV infected subjects were treated with single interferon-α- 2b for 6 months before the trial,and the treat- ment was stopped for the irresponsive cases.Six months later,the irresponsive cases received the combined therapy of interferon-α-2b and autolo- gous HBsAg-loaded DCs for another 6 months (one course containing twice of re-transfusion). The changes of virology,serology and biochem- istry indexes were observed one month after the end of treatment. RESULTS:DCs were cultured in vitro.After proliferation for 6 days,DCs were incubated with HBsAg for 1 day to prepare the specific DCs vaccine.The levels of alanine aminotrans- ferase (ALT) and aspartate aminotransferase (AST) were significant decreased after the com- bined therapy as compared with those before (t=2.976,P<0.01;t=2.049,P<0.05).The re- sponse rate of HBV DNA was 53.7%,and the decrease of HBV DNA copies was greater than or equal to 2log10.Neither the injection times of DCs nor the HBV-carrying time had a correla- tion with the virological responses (r=0.048,P>0.05;r=0.137,P>0.05). CONCLUSION:Combined treatment of au- tologous DCs vaccine and interferon-α-2b has a favorable effect on patients with chronic HBV infection.
What problem does this paper attempt to address?